Microglia induce the transformation of A1/A2 reactive astrocytes via the CXCR7/PI3K/Akt pathway in chronic post-surgical pain

Ting Li, Tongtong Liu, Xuhui Chen, Li Li, Miaomiao Feng, Yue Zhang, Li Wan, Chuanhan Zhang and Wenlong Yao

Abstract

Background: Activated astrocytes play important roles in chronic post-surgical pain (CPSP). Recent studies have shown reactive astrocytes are classified into A1 and A2 phenotypes, but their precise roles in CPSP remain unknown. In this study, we investigated the roles of spinal cord A1 and A2 astrocytes and related mechanisms in CPSP.

Methods: We used a skin/muscle incision and retraction (SMIR) model to establish a rat CPSP model. Microglia, CXCR7, and the phosphoinositide 3-kinase/Akt (PI3K/Akt) signaling pathways were regulated by intrathecal injections of minocycline (a non-specific microglial inhibitor), AMD3100 (a CXCR7 agonist), and LY294002 (a specific PI3K inhibitor), respectively. Mechanical allodynia was detected with von Frey filaments. The changes in microglia, A1 astrocytes, A2 astrocytes, CXCR7, and PI3K/Akt signaling pathways were examined by enzyme-linked immunosorbent assay (ELISA), western blot, and immunofluorescence.

Results: Microglia were found to be activated, with an increase in interleukin-1 alpha (IL-1α), tumor necrosis factor alpha (TNFα), and complement component 1q (C1q) in the spinal cord at an early stage after SMIR. On day 14 after SMIR, spinal cord astrocytes were also activated; these were mainly of the A1 phenotype and less of the A2 phenotype. Intrathecal injection of minocycline relieved SMIR-induced mechanical allodynia and reverted the ratio of A1/A2 reactive astrocytes. The expression of CXCR7 and PI3K/Akt signaling was decreased after SMIR, while they were increased after treatment with minocycline. Furthermore, intrathecal injection of AMD3100 also relieved SMIR-induced mechanical allodynia, reverted the ratio of A1/A2 reactive astrocytes, and activated the PI3K/Akt signaling pathway, similar to the effects produced by minocycline. However, intrathecal injection of AMD3100 did not increase the analgesic effect of minocycline. Last, LY294002 inhibited the analgesic effect and A1/A2 transformation induced by minocycline and AMD3100 after SMIR.

Conclusion: Our results indicated that microglia induce the transformation of astrocytes to the A1 phenotype in the spinal cord via downregulation of the CXCR7/PI3K/Akt signaling pathway during CPSP. Reverting A1 reactive astrocytes to A2 may represent a new strategy for preventing CPSP.

Keywords: Skin/muscle incision and retraction, A1 astrocytes, A2 astrocytes, Microglia, Chronic post-surgical pain
Introduction
Chronic postsurgical pain (CPSP) refers to pain in and around the surgical area that lasts longer than 2 months, excluding pain due to disease recurrence, inflammation, and other factors [1, 2]. About 10–50% of patients experience persistent pain after surgical procedures, such as thoracotomy, cesarean section, radical mastectomy, and inguinal hernia repair. CPSP seriously affects post-operative recovery and the quality of life of the patient [3–5]. However, there is no effective strategy for the treatment and prevention of CPSP. The mechanism underlying CPSP is complex and remains to be elucidated. Previous studies have shown that CPSP is a neuropathic pain caused mainly by surgical damage to peripheral nerves [6]. However, Flatters demonstrated that skin/muscle incision and retraction (SMIR)-induced CPSP lasted at least 22 days without nerve damage [3].

In recent years, much attention has been paid to the role of spinal glial cells in the development and maintenance of pain [7, 8]. Many studies have demonstrated the roles of activated astrocytes in various types of chronic pain, such as neuropathic pain [9, 10], inflammatory pain [11, 12], and bone cancer pain [13]. It has been reported that reactive astrocytes can be classified into A1 and A2 phenotypes, which provide neuroprotective and neurotoxic effects, respectively [14]. Recent studies have demonstrated that reactive astrocytes are involved in Parkinson’s disease, spinal cord injury [15, 16], and traumatic brain injury [17]. However, the roles of A1 and A2 astrocytes in CPSP are unclear.

It is known that activated microglia can induce the transformation of astrocytes into the A1 phenotype by releasing interleukin-1 alpha (IL-1α), tumor necrosis factor (TNF), and complement component 1q (C1q) [14]. Minocycline, a microglial inhibitor, could provide analgesic and anti-inflammatory effects in a variety of pain models, such as neuropathic pain models [9, 10], inflammatory pain models [11, 12], and bone cancer pain models [13]. However, it is yet to be determined whether the phenotypic transformation of A1 and A2 reactive astrocytes is mediated by microglia in CPSP.

CXCR7, a non-classical G-protein-coupled receptor, is involved in CXCL12-mediated cell cycle regulation and cell proliferation [23, 24]. AMD3100, a CXCR7 agonist, has been reported to induce the transformation of microglia into the anti-inflammatory M2 subtype and astrocytes into the neuroprotective A2 subtype [25, 26]. Studies have also documented that CXCR7 signaling plays a role in regulating cell proliferation and differentiation via the phosphoinositide 3-kinase/Akt (PI3K/Akt) signaling pathway [27, 28].

In this study, in order to identify the roles of different phenotypes of reactive astrocytes in CPSP, we first examined changes in A1 and A2 astrocytes in the spinal cord after SMIR. We then investigated the role of microglia in regulating A1/A2 transformation in CPSP, using minocycline. Last, we investigated the molecular mechanism by which microglia-mediated A1/A2 transformation occurred in CPSP by examining the CXCR7/PI3K/Akt signaling pathway.

Material and methods
Animals
Male Sprague-Dawley rats (200–220 g) were supplied from Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, People’s Republic of China. The rats were housed under standard conditions (temperature: 22–25 °C, relative humidity: 45–65%, and 12-h light to dark cycle, with food and water ad libitum). All experiments were approved by the Experimental Animal Care and Use Committee of Tongji Medical College, Huazhong University of Science and Technology, and were in agreement with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.

Skin/muscle incision and retraction
The skin/muscle incision and retraction (SMIR) surgery was carried out, as previously reported [3]. Briefly, the medial skin of the thigh was cut 1.5–2 cm from approximately 4 mm medial to the saphenous vein to reveal the thigh muscles after rats were intraperitoneally injected with 1% sodium pentobarbital (50 mg/kg). The superficial layer of the gracilis muscle was cut 7–10 mm, and then, the muscle was further separated using a blunt dissection technique to allow the micro-dissecting retractor (Biomedical Research Instruments Inc., USA) to be inserted. All prongs of the micro-dissecting retractor were positioned below the superficial layer of the gracilis muscle; then, the skin and superficial muscles of the thigh were retracted by 2 cm to expose the underlying adductor fascia for 1 h. Isoflurane was used to provide additional anesthesia if necessary. The muscles and skin were sutured with 3.0 and 4.0 Vicryl sutures after 1 h. Large absorbent bench underpads were used to cover the rats to reduce the drying of the surgical site and heat loss from the rats. For the sham group, the skin and superficial muscles were cut without retraction.

Intrathecal catheterization and drug administration
Intrathecal catheterization was carried out, as previously reported [22]. Briefly, the PE10 catheters (inner diameter 0.3 mm, outer diameter 0.6 mm) were inserted from L5–L6 spinous processes to the lumbar enlargement 5 days prior to the establishment of SMIR models. The rats were temporarily paralyzed after intrathecal injection of 2% lidocaine (10 μL), indicating the success of catheterization. All rats were allowed to recover for 5 days before experiments.
Minocycline hydrochloride (#M9511, Sigma-Aldrich, USA), a microglial inhibitor, was dissolved in saline and intrathecally injected at a dose of 100 μg/20 μL immediately and for seven consecutive days after SMIR. AMD3100 (S8030, Selleck Chemicals, USA), a CXCR7 agonist, was dissolved in saline and intrathecally injected at a dose of 20 μg/10 μL immediately and for seven consecutive days after SMIR. LY294002 (HY-10108, MCE, USA), a specific antagonist of PI3K, was dissolved in 10% dimethyl sulfoxide (DMSO) and injected intrathecally at a dose of 10 μg/5 μL 15 min before minocycline or AMD300 treatment. The doses of minocycline, AMD3100, and LY294002 were determined based on our preliminary studies and previous reports [22, 29, 30].

**Paw withdrawal threshold test**
As described previously [3, 31], the mechanical paw withdrawal threshold (PWT) test was performed with von Frey filaments (Stoelting, Wood Dale, IL, USA) on days 0, 1, 4, 7, 14, and 21 at 09:00 AM. Briefly, the rats were placed in a separate transparent box with a wire mesh at the bottom that allowed the paws to be fully touched and then allowed to adapt for 40 min. Different von Frey filaments, ranging from 2 to 15 g, were gradually applied for up to 3 s to the mid-plantar area of the right hindpaw in an ascending manner. Sudden claw retraction, shaking, or licking was regarded as a positive reaction. The PWT was defined as the minimum force required to cause a positive reaction at least three times in five tests.

**Enzyme-linked immunosorbent assay analysis**
The rats were sacrificed under deep anesthesia, and L3–L5 spinal segments were immediately removed and homogenized in phosphate-buffered saline (PBS). The supernatants of tissue homogenates were collected and analyzed using rat IL-1α (Elabscience Biotechnology Co., Ltd., Wuhan, China), TNF-α (Elabscience Biotechnology Co., Ltd.), or C1q (LifeSpan BioSciences Inc., USA) ELISA kits, according to the manufacturer’s instructions.

**Western blot analysis**
The rats were sacrificed under deep anesthesia, and L3–L5 spinal segments were immediately removed and homogenized in an ice-cold mixture of radiolabeled precipitation assay lysis buffer, phoshatase inhibitor, and phenylmethylsulfonyl fluoride (Boster Biological Technology, Wuhan, China) and then centrifuged at 12,000 rpm at 4°C for 30 min. The protein concentration was determined using a BCA protein assay kit (Thermo Scientific, USA). The proteins were boiled at 90°C in a loading buffer for 8 min and stored at ~80°C until use. Samples (30–50 μg protein) were loaded and separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to a polyvinylidene fluoride membrane. The membranes were blocked with 5% bovine serum albumin in Tris-buffered saline and Tween 20 (TBST, 0.1%) for 2 h at room temperature, followed by overnight incubation at 4°C with specific primary antibodies: rabbit anti-C3/C3a antibody (A13283, 1:1000, Abclonal, Wuhan, China), rabbit anti-S100A10 antibody (ab187201, 1:500, Abcam, MA, USA), mouse anti-glial fibrillary acidic protein antibody (GFAP, #3670, 1:5000, Cell Signaling Technology, MA, USA), rabbit anti-CXCR7 antibody (ab72100, 1:1000, Abcam), rabbit anti-p-PI3K antibody (AF3241, 1:1000, Affinity, Wuhan, China), mouse anti-PI3K antibody (60225-1-Ig, 1:1000, Proteintech), mouse anti-p-Akt antibody (66444-1-lg, 1:1000, Proteintech), rabbit anti-Akt antibody (10176-2-AP, 1:1000, Proteintech), and mouse anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (AC002, 1:5000, Abclonal). After washing in TBST, the membranes were incubated with horseradish peroxidase (HRP)-conjugated goat anti-mouse secondary antibody (1:5000, Aspen, Wuhan, China) or goat anti-rabbit secondary antibody (1:5000, Aspen, Wuhan, China) for 2 h at room temperature. Finally, the protein bands were detected by SuperLuma ECL Plus HRP Substrate Kit (K22030, Abbkine, Wuhan, China) and exposed using ChemiDoc XR5+ imaging system (Bio-Rad, USA). The intensity of bands was analyzed using System with Image Lab software (Bio-rad Laboratories, standardized against GAPDH, and the band density of the sham group was set as 1.

**Immunofluorescence**
The rats were transcardially perfused with PBS, followed by 4% neutral-buffered paraformaldehyde (PFA). Spinal cord tissue was removed from levels L3–L5, post-fixed overnight in 4% PFA, and then dehydrated in 30% sucrose solution for 2 days at 4°C. The harvested spinal cord samples were sectioned to 20 μm thickness in a cryostat (CM1900, Leica, Germany). The sections were blocked with 5% donkey serum for 1 h at room temperature and incubated with goat anti-ionized calcium-binding adapter molecule 1 (Iba1, ab5076, 1:200, Abcam) overnight at 4°C. Then, the sections were incubated with Alexa Fluor 488-labeled donkey anti-goat secondary antibody (1:100, Jackson ImmunoResearch, West Grove, PA, USA) for 2 h at room temperature.

For double immunofluorescence, the sections were blocked with 5% goat serum and 0.3% Triton X-100 in PBS for 1 h at room temperature and incubated with a mixture of rabbit anti-C3/C3a antibody (A13283, 1:100, Abclonal) and mouse anti-GFAP antibody (#3670, 1:200, Cell Signaling Technology)/goat anti-Iba1 antibody (ab5076, 1:200, Abcam)/mouse anti-neuronal nuclei antibody (NeuN, MAB377, 1:50, Millipore) or rabbit anti-S100A10 antibody (ab187201, 1:100, Abcam) and GFAP/Iba1/NeuN, or rabbit anti-CXCR7 antibody.
(ab72100; 1:50; Abcam) and GFAP/Iba1/NeuN. Then, the sections were incubated with a mixture of secondary antibodies, including Alexa Fluor 594-labeled goat anti-rabbit secondary antibody (1:400; Jackson ImmunoResearch) and Alexa Fluor 488-labeled goat anti-mouse secondary antibody (1:200; Jackson ImmunoResearch), for 2 h at room temperature. Images were captured using a fluorescence microscope (DM2500, Leica, Germany). As described previously [32, 33], the mean fluorescence intensity and the number of Iba1+ cells of microglia were calculated using Image J (National Institutes of Health, Bethesda, MD, USA).

Experimental designs and animal groups
As shown in Fig. 1, there were four experiments in this study.

Experiment 1: Changes in mechanical allodynia and glial expression after SMIR in rats
Sixty rats were randomly allocated to a sham or SMIR group. The PWTs were measured at days 1, 4, 7, 14, and 21 after surgery, and then, the L3–L5 region of the spinal cord was extracted for western blot and immunofluorescent analysis. According to previous studies and our preliminary studies, the activation of spinal microglia was most significant at day 7 after SMIR surgery, while the activation of spinal astrocytes in rats was most significant at day 14 after SMIR surgery [4, 34, 35]. Therefore, we chose the 7th day after the sham operation as a control to study microglial activation and the 14th day after the sham operation as a control to study astrocyte activation.

Experiment 2: The effects of minocycline pretreatment on mechanical allodynia, glial expression, and the CXCR7/PI3K/Akt pathway after SMIR
After SMIR surgery, 40 rats were divided into SMIR+vehicle and SMIR+minocycline groups. The PWTs were measured 30 min before each injection. The L3–L5 region of the spinal cord was collected from the SMIR+ minocycline group at days 7, 14, and 21 after surgery, and SMIR+vehicle group at 14 days after surgery for western blot and immunofluorescence analysis.

Experiment 3: The effects of CXCR7 agonist pretreatment on mechanical allodynia after SMIR
After SMIR surgery, 24 rats were divided into four groups: SMIR+vehicle group, SMIR+minocycline group, SMIR+AMD3100 group, and SMIR+minocycline+AMD3100 group (n = 6 per group). The PWTs were measured 30 min before each injection. The L3–L5 region of the spinal cord was collected from each group 14 days after surgery for western blot and immunofluorescence analysis.

Fig. 1 Experimental designs and animal groups. Experiment 1: changes in pain behavior and glial phenotypes after SMIR in rats. Experiment 2: effects of minocycline pretreatment on mechanical allodynia, glial phenotypes, and the CXCR7/PI3K/Akt pathway after SMIR in rats. Experiment 3: effects of CXCR7 agonist pretreatment on mechanical allodynia after SMIR in rats. Experiment 4: effects of PI3K/Akt pathway inhibitor pretreatment on the analgesic effect of minocycline and AMD3100. WB: western blot; IF: immunofluorescence; ELISA: enzyme-linked immunosorbent assay; SMIR: skin/muscle incision and retraction; AMD3100: CXCR7 agonist; minocycline: microglia inhibitor; LY294002: PI3K inhibitor; PWT: paw withdrawal threshold.
Experiment 4: The effects of PI3K/Akt pathway inhibitor pretreatment on the analgesic effect of minocycline and AMD3100

After SMIR surgery, 30 rats were randomly distributed into five groups: SMIR+vehicle group, SMIR+AMD3100 group, SMIR+minocycline group, SMIR+AMD3100+LY294002 group, and SMIR+minocycline+LY294002 group (n = 6 per group). The L3–L5 region of the spinal cord was collected 14 days after surgery for western blot and immunofluorescence analysis.

Statistical analyses
All data are presented as the mean ± standard error of the mean (SEM). All statistical analyses were conducted using GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA). Two-way repeated measures analysis of variance (ANOVA) followed by Bonferroni’s post hoc test was used for the analysis of the PWT data. One-way ANOVA, followed by Bonferroni’s post hoc test, was used for ELISA, immunofluorescence, and western blot data analysis. Differences with P < 0.05 were considered statistically significant.

Results
Microglia are activated in the spinal cord in the early stages of SMIR
Behavioral testing showed that mechanical PWT was decreased in the ipsilateral hindpaw from days 1 to 21 in the SMIR group, compared with baseline. Compared to sham rats, the SMIR rats exhibited a decreased PWT in the ipsilateral hindpaw from days 1 to 21 (Fig. 2a, group: F(1, 9) = 136.3, P < 0.0001; time: F(5, 45) = 19.58, P < 0.0001; interaction: F(5, 45) = 10.47, P < 0.0001). These results indicated that the CPSP model was successfully induced by SMIR.

Microglial expression in the spinal dorsal horn was examined by immunofluorescent labeling of Iba1. As shown in Fig. 2b, microglia bodies were enlarged with retraction of the protuberances at days 1, 4, and 7 after SMIR. The results of the quantitative analysis showed that compared with the sham group, the mean fluorescent intensity and number of Iba1-positive cells in the spinal cord were significantly increased after SMIR (Fig. 2f, F(3, 12) = 19.1, P < 0.0001; Fig. 2g, F(3, 12) = 35.83, P < 0.0001). The results of the ELISA showed that spinal cord IL-1α, TNFα, and C1q were significantly higher in the SMIR group than in the sham group (Fig. 2c–e, IL-1α: F(2, 6) = 510, P < 0.0001; TNFα: F(2, 6) = 536.2, P < 0.0001; C1q: F(2, 6) = 41.76, P = 0.0003). These indicated that microglia were activated in the spinal cord in the early stages of SMIR.

Astrocytes were activated and mainly expressed as the A1 phenotype in the spinal cord after SMIR
The changes in astrocytes, A1 versus A2, after SMIR were examined by western blot with GFAP, C3, and S100A10. The results show that compared with the sham group, GFAP increased in a time-dependent manner at days 7, 14, and 21 (Fig. 3a, F(5, 36) = 6.295, P = 0.0003). The expression of C3 (a marker for the A1 astrocyte phenotype) was significantly increased at days 7 and 14 after SMIR (Fig. 3b, F(5, 36) = 5.004, P = 0.0014). In contrast, the expression of S100A10 (a marker for the A2 astrocyte phenotype) was decreased at days 7, 14, and 21 after SMIR (Fig. 3c, F(5, 36) = 9.672, P < 0.0001).

We further examined the expression of A1 and A2 phenotypes in the spinal cord by double immunofluorescence. As shown in Fig. 3d, e, C3 and S100A10 were mostly colocalized with GFAP in the superficial region of the spinal cord of the SMIR rats. Compared with sham rats, A1 reactive astrocytes were increased, while A2 reactive astrocytes were decreased 14 days after SMIR. This indicated that reactive astrocytes were mainly expressed as the A1 phenotype in the spinal cord after SMIR.

Minocycline reverted the A1/A2 ratio of reactive astrocytes and relieved mechanical allodynia after SMIR in rats
Minocycline was intrathecally injected immediately and for seven consecutive days after SMIR to investigate the role of microglia in regulating the A1/A2 phenotypic transformation in CPSP. As shown in Fig. 4a, behavioral testing showed that PWT was significantly increased after intrathecal injection of minocycline, compared with the SMIR+vehicle group (group: F(1, 9) = 223.2, P < 0.0001; time: F(5, 45) = 21.52, P < 0.0001; interaction: F(5, 45) = 33.11, P < 0.0001).

Western blot analysis showed that the expression of C3 (a marker for the A1 astrocyte phenotype) was significantly downregulated on days 7, 14, and 21 after minocycline treatment (Fig. 4b, F(3, 16) = 12.64, P = 0.0002), while the expression of S100A10 (a marker for the A2 astrocyte phenotype) was upregulated on days 7 and 14 after minocycline treatment (Fig. 4c, F(3, 16) = 6.082, P = 0.0058). Similarly, double immunofluorescence showed that compared with the SMIR+vehicle group, the expression of the A1 astrocytic phenotype was significantly decreased, while the expression of the A2 astrocytic phenotype was significantly increased in the SMIR+minocycline group (white arrow in Fig. 4d, e). These results demonstrated that inhibition of microglial activation reverted the A1/A2 ratio of reactive astrocytes and relieved mechanical allodynia after SMIR in rats.

The CXCR7 and PI3K/Akt signaling pathways are involved in CPSP
The molecular mechanisms of microglia-regulated astrocyte polarization in CPSP remained unclear in the studies above. CXCR7 is involved in inflammatory communication...
between glial cells and neurons, which regulates the polarization of glial cells. Therefore, we first examined changes in CXCR7 and its endogenous ligand CXCL12 in the spinal cords of SMIR rats. Double immunofluorescence staining showed that CXCR7 was expressed mostly in astrocytes and, to a small extent, in microglia and neurons (Fig. 5c). As shown in Fig. 5a, b, western blot analysis showed that compared with the sham group, the expression of CXCR7 was reduced in the spinal cord in the SMIR group ($F(5, 18) = 5.831, P = 0.0023$), while the expression of its ligand CXCL12 was unchanged. In contrast, after treatment with minocycline, the expression of CXCR7 was significantly increased at days 7, 14, and 21 (Fig. 5f, $F(3, 12) = 28.04, P < 0.0001$).

The PI3K/Akt pathway was examined as it is an important signaling pathway that regulates cell growth, differentiation, and migration. Western blot analysis showed that compared with the sham group, the expression of p-PI3K was significantly downregulated at days 7, 14, and 21 after SMIR (Fig. 5d, $F(5, 18) = 24.02, P < 0.0001$), which was
reversed after minocycline treatment (Fig. 5g, $F(3, 12) = 57.38, P < 0.0001$). The expression of p-Akt was significantly downregulated at days 4, 7, 14, and 21 after SMIR (Fig. 5e, $F(5, 18) = 3.558, P = 0.0206$), which was reversed after minocycline treatment (Fig. 5h, $F(3, 8) = 10.16, P = 0.0042$). These results indicate that minocycline can prevent SMIR-induced downregulation of the CXCR7 and PI3K/Akt signaling pathways.

The CXCR7 agonist AMD3100 has similar effects to minocycline in SMIR but has no synergistic effects when combined with minocycline

To further investigate the role of CXCR7 in the microglia-mediated phenotypic transformation of reactive astrocytes, the specific CXCR7 agonist AMD3100 was intrathecally injected alone or in combination with minocycline immediately and for seven consecutive days after SMIR. As shown in Fig. 6a, behavioral testing showed that the PWT was significantly increased after intrathecal injections of AMD3100. However, the analgesic effect of AMD3100 alone was not comparable with that of minocycline alone or in combination with AMD3100 (group: $F(3, 15) = 27.32, P < 0.0001$; time: $F(5, 25) = 7.841, P = 0.0001$; interaction: $F(15, 75) = 6.502, P < 0.0001$). Western blot analysis showed that after injection of AMD3100, minocycline, or both, the expressions of CXCR7, p-PI3K, and p-Akt were significantly increased in the spinal cords of SMIR rats (Fig. 6b, for CXCR7: $F(3, 16) = 6.523, P = 0.0043$; Fig. 6e, for p-PI3K: $F(3, 12) = 12.07, P = 0.0006$; Fig. 6f, for p-Akt: $F(3, 12) = 19.06, P < 0.0001$). Moreover, the expression of C3 (a marker for the A1 astrocyte phenotype) was significantly downregulated (Fig. 6c, $F(3, 16) = 28.07, P < 0.0001$), while the expression of S100A10 (a marker for the A2 astrocyte phenotype) was upregulated (Fig. 6d, $F(3, 16) = 9.484, P = 0.0008$).

These results suggest that CXCR7 is one of the important downstream receptors for minocycline-induced behavioral improvement, upregulation of the PI3K/Akt signaling pathway, and transformation of astrocytes into the A2 subtype.
LY294002, a specific PI3K inhibitor, inhibited the analgesic effect and A1/A2 transformation induced by minocycline and AMD3100 after SMIR

To verify whether the PI3K/Akt pathway is the downstream mechanism by which microglia and CXCR7 regulate the transformation of reactive astrocytes during CPSP, LY294002, a specific PI3K inhibitor, was intrathecally administered prior to minocycline or AMD3100 injection. As shown in Fig. 7a, behavioral tests showed that the administration of LY294002 significantly antagonized the analgesic effects of minocycline or AMD3100 (group: F(1, 5) = 51.17, P = 0.0004; time: F(5, 25) = 5.182, P = 0.0021; interaction: F(5, 25) = 11.37, P < 0.0001, vs SMIR+vehicle group; group: F(1, 5) = 28.89, P = 0.003; time: F(5, 25) = 15.41, P < 0.0001; interaction: F(5, 25) = 3.912, P = 0.0093, vs SMIR+AMD3100 group). Moreover, the western blot results showed that LY294002 pre-treatment significantly hindered the downregulation of C3 (a marker for the A1 astrocyte phenotype) (Fig. 7b, F(4, 20) = 35.28, P < 0.0001) and the upregulation of S100A10 (a marker for the A2 astrocyte phenotype) (Fig. 7c, F(4, 20) = 20.93, P < 0.0001) induced by minocycline or AMD3100. These results suggested that minocycline and AMD3100 reverted the A1/A2 ratio of reactive astrocytes and relieved mechanical allodynia in rats after SMIR.
In the present study, we demonstrated that (1) during SMIR-induced CPSP, astrocytes were activated and mainly manifested as the A1 phenotype after the activation of microglia in the spinal cord; (2) minocycline, a microglial inhibitor, relieved SMIR-induced mechanical allodynia and reverted the ratio of A1/A2 reactive astrocytes; (3) AMD3100, a CXCR7 agonist, relieved SMIR-induced mechanical allodynia, reverted the ratio of A1/A2 reactive astrocytes; and (4) the CXCR7 and PI3K/Akt signaling pathways are involved in CPSP in the dorsal horn of the spinal cord.

**Discussion**

In the present study, we demonstrated that (1) during SMIR-induced CPSP, astrocytes were activated and mainly manifested as the A1 phenotype after the activation of microglia in the spinal cord; (2) minocycline, a microglial inhibitor, relieved SMIR-induced mechanical allodynia and reverted the ratio of A1/A2 reactive astrocytes; (3) AMD3100, a CXCR7 agonist, relieved SMIR-induced mechanical allodynia, reverted the ratio of A1/A2 reactive astrocytes; and (4) the CXCR7 and PI3K/Akt signaling pathways are involved in CPSP in the dorsal horn of the spinal cord.
A2 reactive astrocytes, and activated the PI3K/Akt signaling pathway, which was similar to the effects produced by minocycline; however, intrathecal injection of AMD3100 did not increase the analgesic effect of minocycline; and (4) LY294002, a specific PI3K inhibitor, inhibited the analgesic effect and A1/A2 transformation induced by minocycline and AMD3100 after SMIR. These results indicate that A1 and A2 astrocytes play different roles in the development of CPSP. The transformation of A1/A2 astrocytes during the development of CPSP was regulated by microglia, and the CXCR7/PI3K/Akt pathway is considered to be the downstream mechanism involved.

Previous studies have shown that SMIR induces CPSP that lasts at least 22 days without nerve injury [3]. Three rat pain models are similar to the SMIR model: the thoracotomy model, the gastrocnemius incision model, and the paw incision model. Unlike the thoracotomy model, where nerve degeneration leads to persistent pain [36], the SMIR model causes persistent pain without nerve injury. In addition, the paw incision model and gastrocnemius incision model induce mechanical allodynia for up to 4 days and 8 days, respectively, while the SMIR model induces mechanical allodynia for at least 3 weeks [3]. Therefore, we used the SMIR model in this study and found that it could induce persistent postoperative pain.

It is known that activated astrocytes are involved in the maintenance of chronic pain [7, 37]. Recent studies have also demonstrated that reactive astrocytes have two different phenotypes, A1 and A2, which play neurotoxic and neuroprotective roles, respectively [14]. Neurotoxic

![Fig. 6](image-url)
A1 astrocytes, which secrete toxic factors that kill mature oligodendrocytes and neurons, have been shown to be involved in a variety of neurodegenerative diseases [38] and spinal cord injury [39]. The detrimental role of A1 astrocytes in traumatic brain injury has also been well documented [40]. A2 reactive astrocytes have been shown to play a neuroprotective role in traumatic brain injury [17]. In the present study, we observed an imbalanced astrocytic polarization of A1 and A2 in the spinal cord of the rat SMIR model. During the development of CPSP, reactive astrocytes were mainly expressed as A1 astrocytes, with very few A2 astrocytes found. When mechanical allodynia was relieved in SMIR rats by intrathecal injection of minocycline or AMD3100, the expression of A1 astrocytes was decreased, and the expression of A2 astrocytes was increased. These results indicate that A1 astrocytes contribute to pain development, while A2 astrocytes are beneficial for relieving pain. Regulating the ratio of A1/A2 astrocytes may represent a new strategy for preventing CPSP.

A previous study showed that A1 astrocytes were induced by activated microglia via the secretion of IL-1α, TNFα, and C1q [14]. Qian et al. found that microglia induced the formation of A1 astrocytes by activating the Notch-Stat3 pathway in spinal cord injury [16]. Microglia induced the transformation of astrocytes into a neuroprotective phenotype by downregulating the P2Y1 receptor after brain trauma [41]. A2 astrocytes are induced by damaged neurons via the secretion of prokineticin-2 [42]. Milk fat globule epidermal growth factor 8 can decrease the expression of A1 astrocytes and increase the expression of A2 astrocytes by upregulating the activation of the PI3K/Akt pathway and downregulating the activation of the nuclear factor kappa-light-chain-enhancer of activated B cell pathway [43]. In addition, many studies suggested that microglia were activated in the early stages of chronic pain and thus appear to be involved in the initiation of chronic pain [44–47]. Consistent with this evidence, we found that microglial activation occurred earlier than astrocytic activation after SMIR and was accompanied by increased IL-1α, TNFα, and C1q levels in the spinal cord. Moreover, reactive astrocytes were mainly expressed as the A1 phenotype in the spinal cord after SMIR. These results suggested that A1 reactive astrocytes were induced by microglia during CPSP.

Minocycline, which selectively inhibits the activation of microglia, has no direct effect on neurons or astrocytes [44]. As a second-generation tetracycline, it has antibacterial and anti-inflammatory effects and also has antioxidant and anti-apoptotic effects [48]. In addition, minocycline is emerging as a promising therapy for chronic pain due to its good lipid solubility, easy passage
through the blood-brain barrier, and analgesic effects in a variety of pain models [44, 49]. Choi et al. have shown that minocycline alleviated the development of mirror pain by inhibiting the production of IL-1β from microglia and suppressing astrocytic activation in inflammatory pain models [21]. In line with this, our results show that the intrathecal injection of minocycline prevents SMIR-induced mechanical allodynia. A1 astrocytes were significantly downregulated, and A2 astrocytes were dramatically upregulated after intrathecal injections of minocycline. These results indicated that minocycline relieved CPSP by reverting the ratio of A1/A2 astrocytes. They also confirmed that A1 reactive astrocytes were induced by microglia during CPSP.

CXCR7 is involved in inflammatory communication between glial cells and neurons, which regulates the polarization of glial cells. Odemis et al. found that CXCR7 was expressed on the surface of astrocytes in the CNS [50]. However, some studies found that CXCR7 was expressed in both astrocytes and microglia [51]. CXCR7 promotes cell maturation, differentiation, polarization, and migration when combined with its ligand CXCL12 [52, 53]. In addition, studies have shown that G-protein-coupled receptor kinase 2 (FGF2/FGFR1) pathway resulted in an increase in A1 astrocytes after infrasound damage [58]. For example, Zou et al. demonstrated that the inhibition of CXCR7 small interfering RNA or CXCR7 knockout animals can be considered to further confirm the function of CXCR7 as the downstream mediator in microglia, our results indicate that the PI3K/Akt signaling pathway is an essential downstream mechanism by which microglia and CXCR7 regulate the transformation of reactive astrocytes during CPSP.

There is a limitation to our study. Due to the lack of effective CXCR7 inhibitors, we did not investigate the effect of inhibition of CXCR7 signaling on the analgesic effect of minocycline and A1/A2 expression. Although CXCR7 small interfering RNA or CXCR7 knockout animals can be considered to further confirm the function of CXCR7 as the downstream mediator in microglia, our results suggest that there may be other mechanisms involved in the induction of A1 astrocytes by microglia. For example, there may be other mechanisms involved in the analgesic effect of minocycline alone or in combination with A1/A2 expression. Although CXCR7 small interfering RNA or CXCR7 knockout animals can be considered to further confirm the function of CXCR7 as the downstream mediator in microglia, our results suggest that there may be other mechanisms involved in the induction of A1 astrocytes by microglia. For example, Zou et al. demonstrated that the inhibition of the fibroblast growth factor 2/fibroblast growth factor 2, receptor 1 (FGF2/FGFR1) pathway resulted in an increase in A1 astrocytes after infrasound damage [58]. Therefore, there are other receptors and signaling pathways related to the unbalanced polarization of astrocytes toward the A1 phenotype in the development of CPSP, which requires further study.

This study demonstrated the different roles of A1 and A2 astrocytes in the development of CPSP, but the detailed mechanism by which they regulate pain was not...
explored. A previous study showed that mitochondrial dysfunction in A1 astrocytes caused inflammation and neuronal death, which promoted the development of neurodegenerative diseases [59]. In rat models of Alzheimer’s disease, A1 reactive astrocytes may drive neuronal death by releasing D-serine, which is the agonist for excess glutamate to activate extrasynaptic N-methyl-D-aspartate receptors [60]. Bone mesenchymal stem cell-derived exosomes have been shown to inhibit the production of A1 neurotoxic astrocytes, accompanied by decreased neuronal apoptosis, axonal regeneration, and functional recovery after spinal cord injury [61]. Therefore, A1 astrocytes may promote the development of CPSP by releasing D-serine and pro-inflammatory factors that impair synaptic plasticity as well as by inducing neuronal and axonal injury and neuroinflammation. In contrast, A2 astrocytes promote neuronal survival and tissue repair by secreting neuroprotective factors. Studies have shown that the increased reactivity of A2 astrocytes was accompanied by improvements in mitochondrial energy metabolism, a decrease in pro-inflammatory factors, and an increase in neuroprotective factors such as brain-derived neurotrophic factor and glial cell-derived neurotrophic factor [42, 59, 62]. Therefore, the role of A1 astrocytes in regulating synaptic plasticity, energy metabolism, and neuroinflammation during chronic pain and the mechanism of A2 astrocytes in inhibiting the development of pain require further study.

**Conclusion**

This study is the first to show that A1 astrocytes contribute to the development of CPSP, while A2 astrocytes are beneficial for relieving CPSP. Microglia induced the transformation of astrocytes to the A1 phenotype in the spinal cord by reducing the activation of the CXCR7/PI3K/Akt signaling pathway during CPSP (Fig. 8). Reverting A1 reactive astrocytes to A2 astrocytes may represent a new strategy for preventing CPSP. However, the precise roles of A1 and A2 astrocytes in regulating CPSP require further study.

**Abbreviations**

A: AMD3100; ANOVA: Analysis of variance; BL: Baseline; C1q: Complement component 1q; CPSP: Chronic post-surgical pain; DAP: Nuclear staining; DMSO: Dimethyl sulfoxide; ELISA: Enzyme-linked immunosorbent assay; FGF2: Fibroblast growth factor 2; FGFR1: Fibroblast growth factor 2, receptor 1; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; GFAP: Glial fibrillary acidic protein; HRP: Horseradish peroxidase; Iba1: Ionized calcium-binding adapter molecule 1; IL-1α: Interleukin-1 alpha;
ipsi: ipsilateral; LA: LY294002 + AMD3100; LM: LY294002 + minocycline; M: Minocycline; NeuN: Neuronal nuclei; PBS: Phosphate buffered saline; PFA: Paraformaldehyde; PI3K: Phosphoinositide 3-kinase; PWT: Paw withdrawal threshold; SMIR: Skin/muscle incision and retraction; TBST: Tris-buffered saline and Tween; TNF: Tumor necrosis factor; WB: Western blot

Acknowledgements
We would like to thank Editage (www.editage.cn) for English language editing.

Authors’ contributions
WLY conceived the project and supervised all experiments. TL and WLY wrote the manuscript. TL, TTL, XHC, LL, and MMF performed work on behavioral tests, western blot, ELISA, and immunofluorescence. YZ, LW, CHZ, and WLY worked on intrathecal catheterization, drug administration, and statistical analysis. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of People’s Republic of China (grant nos. 81800476, 81171158 and 81600965) and the Natural Science Foundation of Hubei Province (grant no. 2019CFB444).

Availability of data and materials
The data and materials supporting the conclusions of this study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
All experiments were approved by the Experimental Animal Care and Use Committee of Tongji Medical College, Huazhong University of Science and Technology, and were in agreement with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, People’s Republic of China. 2Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, People’s Republic of China. 3Department of Physiology, Huazhong University of Chinese Medicine, Wuhan 430065, Hubei Province, People’s Republic of China.

Received: 16 April 2020 Accepted: 7 July 2020
Published online: 14 July 2020

References
1. Song J, Ying Y, Wang W, Liu X, Xu X, Wei X, Ruan X. The role of P2X7R/ERK signaling in dorsal root ganglia satellite glial cells in the development of chronic postsurgical pain induced by skin/muscle incision and retraction (SMIR). Brain Behav Immun. 2018;69:180–9.
2. Wooden SR. Chronic postsurgical pain. Annu Rev Nurs Res. 2017;35:91–115.
3. Flatters SJ. Characterization of a model of persistent postoperative pain evoked by skin/muscle incision and retraction (SMIR). Pain. 2008;135:119–30.
4. Ying YL, Wei XH, Xu XB, She SZ, Zhou LJ, Lv J, Li D, Zheng B, Liu XG. Overexpression of P2X7 receptors in spinal glial cells contributes to the development of chronic postsurgical pain induced by skin/muscle incision and retraction (SMIR) in rats. Exp Neuro. 2014;261:836–43.
5. Mejdahl MK, Andersen KG, Gartner R, Kroman N, Kehlet H. Persistent pain and sensory disturbances after treatment for breast cancer: six year nationwide follow-up study. BMJ. 2013;346:f1865.
6. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006;367:1618–25.
7. Li T, Chen X, Zhang C, Zhang Y, Yao W. An update on reactive astrocytes in chronic pain. J Neuroinflamm. 2019;16:140.
8. Eto K, Kim SK, Takeda I, Nabejuka J. The roles of cortical astrocytes in chronic pain and other brain pathologies. Neurosci Res. 2018;126:3–8.
9. Vega-Avelaira D, Moss A, Fitzgerald M. Age-related changes in the spinal cord microglial and astrocytic response profile to nerve injury. Brain Behav Immun. 2007;21:167–73.
10. Stueiss SL, Crisp T, McBurney DL, Schechter JB, Lovell JA, Cruce WL. Neuropathic pain in aged rats: behavioral responses and astrocytic activation. Exp Brain Res. 2001;137:219–27.
11. Raghavendra V, Tanga FY, DeLeo JA. Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci. 2004;20:467–73.
12. Swietzer SM, Colburn RW, Rutkowski M, DeLeo JA. Acute peripheral inflammation induces moderate glial activation and spinal IL-1beta expression that correlates with pain behavior in the rat. Brain Res. 1999;829:209–21.
13. Lu C, Ly S, Sun B, Sun Y, Hou B, Zhang Y, Ma Z, Gu X. Intrathecal injection of JWH-015 attenuates bone cancer pain via time-dependent modification of pro-inflammatory cytokines expression and astrocytes activity in spinal cord. Inflammation. 2015;38:1980–90.
14. Liddle SK, Gutterplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE, Chung WS, Peterson TC, et al. Neurotactic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–7.
15. Yun SP, Kam TJ, Penacker N, Kim S, Oh Y, Park JS, Kwon SH, Park YJ, Karuppagounder SS, Park H, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease. Nat Med. 2018;24:931–8.
16. Qian D, Li L, Rong Y, Liu W, Wang Q, Zhou Z, Gu C, Huang Y, Zhao X, Chen J, et al. Blocking Notch signal pathway suppresses the activation of neurotactic A1 astrocytes after spinal cord injury. Cell Cycle. 2019;18:3010–29.
17. Myer DJ, Garkoff GG, Lee SM, Hovda DA. Sofroniew MV. Essential protective roles of reactive astrocytes in traumatic brain injury. Brain. 2006;129:2761–72.
18. Zhang X, Xu Y, Wang J, Zhou Q, Pu S, Jiang W, Du D. The effect of intrathecal administration of glial activation inhibitors on dorsal horn BDNF overexpression and hind paw mechanical allodynia in spinal nerve ligated rats. J Neural Transm (Vienna). 2012;119:329–36.
19. Van Wilde P, Roussette T, Kociz T, Heyen R, Van Zundert J, Roubos EW, Vissers K. Effects of chronic administration of amitryptiline, gabapentin and minocycline on spinal brain-derived neutotrophic factor expression and neuropathic pain behavior in a rat chronic constriction injury model. Reg Anesth Pain Med. 2013;38:124–30.
20. Nie H, Zhang H, Weng HR. Minocycline prevents impaired glial glutamate uptake in the spinal sensory synapses of neuropathetic rats. Neuroscience. 2010;170:901–12.
21. Choi HS, Roh DH, Yoon SY, Moon JY, Cho SR, Kwon SG, Kang SY, Han HI, Kim HW, Beitz AJ, et al. Microglial interleukin-1beta in the ipsilateral dorsal horn inhibits the development of mirror-image contralateral mechanical allodynia through astrocyte activation in a rat model of inflammatory pain. Pain. 2015;156(6):1046–59.
22. Song ZP, Xiong BR, Guan XH, Cao F, Manyande A, Zhou YQ, Zheng H, Tian YK. Minocycline attenuates bone cancer pain in rats by inhibiting NF-κB in spinal astrocytes. Acta Pharmacol Sin. 2016;37:753–62.
23. Abe P, Wust HM, Arnold SJ, de Pavet SA, Stumrn CR. CXCL12-mediated feedback from granule neurons regulates generation and positioning of new neurons in the dentate gyrus. Glia. 2018;66:1566–75.
24. Wang Y, Xu P, Qiu L, Zhang M, Huang Y, Zheng JC. CXCR7 participates in CXCL12-mediated cell cycle and proliferation regulation in mouse neuron progenitor cells. Curr Mol Med. 2016;16:738–46.
25. Das S, Mishra RP, Chandia S, Ganju L, Singh SB. CXCR7: a key neuroprotective molecule against alzheimer histopathology in mice and subsequent memory impairment. Brain Behav Immun. 2019;92:239–37.
26. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol. 2009;75:1240–7.
27. Hao H, Hu S, Chen H, Bu D, Zhu L, Xu C, Chu F, Hua X, Tang Y, Sun X, et al. Loss of endothelial CXCR7 impairs vascular homeostasis and cardiac remodeling after myocardial infarction: implications for cardiovascular drug discovery. Circulation. 2017;135:1253–64.
28. Zhang M, Qiu L, Zhang Y, Xu D, Zheng JC, Jiang L. CXCL12 enhances angiogenesis through CXCR7 activation in human umbilical vein endothelial cells. Sci Rep. 2017;7:8289.
29. Rong H, Zhao Z, Feng J, Lei Y, Wu H, Sun R, Zhang Z, Hou B, Zhang W, Sun Y, et al. The effects of dexmedetomidine pretreatment on the pro- and anti-inflammatory systems after spinal cord injury in rats. Brain Behav Immun. 2017;64:195–207.

30. Xiong F, Kong C, Bai L, Qian J, Yuan J, Li Z, Zhang W, Xu J. CXCL12/CXCR4 signaling mediated ERK1/2 activation in spinal cord contributes to the pathogenesis of postoperative pain in rats. Mol Pain. 2017;13:207144767.

31. Chen X, Li Z, Zhang B, Hu R, Li J, Feng M, Yao W, Zhang C, Wan L, Zhang Y. Alleviation of mechanical allodynia by 14,15-epoxyeicosatrienoic acid in a central poststroke pain model: possible role of allopregnanolone and delta-subunit-containing gamma-aminobutyric acid A receptors. J Pain. 2019;20:57–91.

32. Xu N, Tang XH, Pan W, Xie ZM, Zhang GF, Ji MH, Yang JJ, Zhou MT, Zhou ZQ. Spared nerve injury increases the expression of microglia M1 markers in the prefrontal cortex of rats and provokes depression-like behaviors. Front Neurosci. 2017;11:209.

33. Li F, Ma Q, Zhao H, Wang R, Tao Z, Fan Z, Zhang S, Li G, Luo Y. L-3-n-Butylphthalide reduces ischemic stroke injury and increases M2 microglial polarization. Metab Brain Dis. 2018;33:1995–2003.

34. Wang W, Zhong X, Li Y, Gou D, Du S, Wen L, Ying Y, Yang T, Wei XH. Rostral ventromedial medulla-mediated descending facilitation following P2X7 receptor activation is involved in the development of chronic post-operative pain. J Neurochem. 2019;149:760–80.

35. Liu ZY, Song ZW, Guo SW, He JS, Wang SY, Zhu JG, Yang HL, Liu J. CXCL12/CXCR4 signaling contributes to neuropathic pain via central sensitization mechanisms in a rat spinal nerve ligation model. CNS Neurosci Ther. 2019;25:922–36.

36. Buvanendran A, Kroin JS, Kerns JM, Nagalla SN, Tuman KJ. Characterization of a new animal model for evaluation of persistent postthoracotomy pain. Anesth Analg. 2004;99:1453–60.

37. Lee S, Zhao YQ, Ribeiro-da-Silva A, Zhang J. Distinctive response of CNS glial cells in orofacial pain associated with injury, infection and inflammation. Mol Pain. 2010;6:79.

38. Chun H, Lee CJ. Reactive astrocytes in Alzheimer’s disease: a double-edged sword. Neurosci Res. 2018;126:44–52.

39. Okada S, Hara M, Kobayakawa K, Matsumoto Y, Nakashima Y. Astrocyte reactivity and astrogliosis after spinal cord injury. Neurosci Res. 2018;126:39–43.

40. Clark D, Perreau VM, Shultz SR, Brady RD, Lei E, Dixit S, Taylor JM, Beart PM, Boon WC. Inflammation in traumatic brain injury: roles for toxic A1 astrocytes and microglial-astrocytic crosstalk. Neurochem Res. 2019;44:1410–24.

41. Shinozaki Y, Shibata K, Yoshida K, Shigetomi E, Gachet C, Ikenaka K, Tanaka M. Knockdown of the CXCL12/CXCR7 chemokine pathway results in learning deficits and neural progenitor maturation impairment in mice. Brain Behav Immun. 2019;85:697–710.

42. Boldajipour B, Mahabaleshwar H, Kandesh E, Reichman-Fried M, Blaser H, Minina S, Wilson D, Xu Q, Raz E. Control of chemokine-guided cell migration by Ligand sequestration. Cell. 2008;132:463–73.

43. Sanchez-Alandiz JA, Haege S, Mueller W, Pla R, Mackay F, Schutz S, Lopez-Bendito G, Stumm R, Marín O. Cxcr7 controls neuronal migration by regulating chemokine responsiveness. Neuron. 2011;69:77–90.

44. Lipert J, Odemis V, Engele J. Gzlk is an essential regulator of Cxcr7 signalling in astrocytes. Cell Mol Neurobiol. 2013;33:111–8.

45. Cavallo D, Landucci E, Gerace E, Lana D, Ugolini F, Henley JM, Giovannini MG, Pellegrini-Gampeeiro DE. Neuroprotective effects of mGluR5 activation through the PI3K/Akt pathway and the molecular switch of AMPA receptors. Neuropharmacology. 2020;162:107810.

46. Lu Y, Lei S, Wang N, Li W, Li W, Zheng J, Giri PK, Lu H, Chen X, Zhuo Z, et al. Protective effect of minocycline against ketamine-induced injury in neural stem cell: involvement of PI3K/Akt and GSK-3 beta pathway. Front Mol Neurosci. 2016;9:135.

47. Shi X, Cai X, Di W, Li J, Xu X, Zhang A, Qi W, Zhou Z, Fang Y. MFG-E8 selectively inhibited Abeta-induced microglial M1 polarization via NF-kappaB and PI3K-Akt pathways. Mol Neurobiol. 2017;54:7777–88.

48. Zou LH, Shi JY, He H, Jiang SM, Huo FF, Wang XM, Wu F, Ma L. Effects of FGF2/FGFR1 pathway on expression of A1 astrocytes after infrasound exposure. Front Neurosci. 2019;13:3429.

49. Joshi AU, Minhas PS, Liddelow SA, Haleselassie B, Andeasson KI, Dorn GN, Mochly-Rosen D. Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration. Nat Neurosci. 2019;22:1635–48.

50. Balu DT, Pantazopoulos H, Huang C, Muszynski K, Harvey TL, Uno Y, Ronbaugh JM, Galloway CR, Botz-Zapp C, Berretta S, et al. Neurotrophic astrocytes express the d-serine synthesizing enzyme, serine racemase, in Alzheimer’s disease. Neurobiol Dis. 2019;130:105411.

51. Liu W, Wang Y, Gong F, Rong Y, Luo Y, Tang P, Zhou Z, Zhou Z, Xu T, Jiang T, et al. Exosomes derived from bone mesenchymal stem cells repair traumatic spinal cord injury by suppressing the activation of A1 neurotrophic reactive astrocytes. J Neurotrauma. 2019;36:469–84.

52. Fujita A, Yamaguchi H, Yamasaki R, Cui Y, Matsuoka Y, Yamada K, Kira JI. Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model. J Neuroinflammation. 2018;15:227.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.